verapamil has been researched along with Koch's Disease in 11 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades." | 7.80 | Acquired resistance of Mycobacterium tuberculosis to bedaquiline. ( Andries, K; Coeck, N; de Jong, BC; Gevers, T; Koul, A; Lounis, N; Thys, K; Villellas, C; Vranckx, L, 2014) |
| "Verapamil enhances the sensitivity of Mycobacterium tuberculosis to anti-tuberculosis (TB) drugs, promotes the macrophage anti-TB ability, and reduces drug resistance, but its mechanism is unclear." | 4.31 | Verapamil Regulates the Macrophage Immunity to ( Bai, X; Cui, R; Gong, W; Liang, Y; Song, L; Wang, J; Wang, L; Wu, X; Yang, Y; Zhang, J; Zhao, W, 2023) |
| "Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades." | 3.80 | Acquired resistance of Mycobacterium tuberculosis to bedaquiline. ( Andries, K; Coeck, N; de Jong, BC; Gevers, T; Koul, A; Lounis, N; Thys, K; Villellas, C; Vranckx, L, 2014) |
| "New and improved treatments for tuberculosis (TB) are urgently needed." | 1.46 | Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis. ( Delorme, V; Jang, J; Jeong, J; Kim, G; Kim, R; Park, DE; Woo, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ang, CW | 1 |
| Lee, BM | 1 |
| Jackson, CJ | 1 |
| Wang, Y | 1 |
| Franzblau, SG | 1 |
| Francisco, AF | 1 |
| Kelly, JM | 1 |
| Bernhardt, PV | 1 |
| Tan, L | 1 |
| West, NP | 1 |
| Sykes, ML | 1 |
| Hinton, AO | 1 |
| Bolisetti, R | 1 |
| Avery, VM | 1 |
| Cooper, MA | 1 |
| Blaskovich, MAT | 1 |
| Shyam, M | 1 |
| Verma, H | 1 |
| Bhattacharje, G | 1 |
| Mukherjee, P | 1 |
| Singh, S | 1 |
| Kamilya, S | 1 |
| Jalani, P | 1 |
| Das, S | 1 |
| Dasgupta, A | 1 |
| Mondal, A | 1 |
| Das, AK | 1 |
| Singh, A | 1 |
| Brucoli, F | 1 |
| Bagnéris, C | 1 |
| Dickman, R | 1 |
| Basavanakatti, VN | 1 |
| Naresh Babu, P | 1 |
| Sankaran, V | 1 |
| Dev, A | 1 |
| Sinha, BN | 1 |
| Bhakta, S | 1 |
| Jayaprakash, V | 1 |
| Gong, W | 1 |
| Cui, R | 1 |
| Song, L | 1 |
| Yang, Y | 1 |
| Zhang, J | 1 |
| Liang, Y | 1 |
| Bai, X | 1 |
| Wang, J | 1 |
| Wang, L | 1 |
| Wu, X | 1 |
| Zhao, W | 1 |
| Lake, MA | 1 |
| Adams, KN | 2 |
| Nie, F | 1 |
| Fowler, E | 1 |
| Verma, AK | 1 |
| Dei, S | 1 |
| Teodori, E | 1 |
| Sherman, DR | 1 |
| Edelstein, PH | 2 |
| Spring, DR | 1 |
| Troll, M | 1 |
| Ramakrishnan, L | 2 |
| Özgür, D | 1 |
| Ersoy, L | 1 |
| Ülger, M | 1 |
| Tezcan Ülger, S | 1 |
| Aslan, G | 1 |
| Jang, J | 1 |
| Kim, R | 1 |
| Woo, M | 1 |
| Jeong, J | 1 |
| Park, DE | 1 |
| Kim, G | 1 |
| Delorme, V | 1 |
| Xu, J | 1 |
| Tasneen, R | 1 |
| Peloquin, CA | 1 |
| Almeida, DV | 1 |
| Li, SY | 1 |
| Barnes-Boyle, K | 1 |
| Lu, Y | 1 |
| Nuermberger, E | 1 |
| Andries, K | 1 |
| Villellas, C | 1 |
| Coeck, N | 1 |
| Thys, K | 1 |
| Gevers, T | 1 |
| Vranckx, L | 1 |
| Lounis, N | 1 |
| de Jong, BC | 1 |
| Koul, A | 1 |
| Srikrishna, G | 1 |
| Gupta, S | 1 |
| Dooley, KE | 1 |
| Bishai, WR | 1 |
| Parumasivam, T | 1 |
| Chan, JG | 1 |
| Pang, A | 1 |
| Quan, DH | 1 |
| Triccas, JA | 1 |
| Britton, WJ | 1 |
| Chan, HK | 1 |
| Takaki, K | 1 |
| Connolly, LE | 1 |
| Wiedenhoft, H | 1 |
| Winglee, K | 1 |
| Humbert, O | 1 |
| Cosma, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for verapamil and Koch's Disease
| Article | Year |
|---|---|
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles; | 2022 |
Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Calcium Channel Blockers; Ion Transport; Iron Ch | 2022 |
Verapamil Regulates the Macrophage Immunity to
Topics: Animals; Calcium; Cytokines; Interleukin-12; Macrophages; Mice; Mycobacterium tuberculosis; NF-kappa | 2023 |
The human proton pump inhibitors inhibit
Topics: Antitubercular Agents; Bacterial Proteins; Drug Tolerance; Humans; Macrophages; Microbial Sensitivit | 2023 |
[Investigation of Efflux Pump Genes in Resistant Mycobacterium tuberculosis Complex Clinical Isolates Exposed to First Line Antituberculosis Drugs and Verapamil Combination].
Topics: Antitubercular Agents; Bacterial Proteins; DNA, Complementary; Humans; Isoniazid; Microbial Sensitiv | 2023 |
Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Imidazoles; Microbi | 2017 |
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Biological Availability; Calcium Channel Blockers; Clofazimine; Colo | 2018 |
Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Base Sequence; Clofazimine; Diarylquinolines; Dr | 2014 |
Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.
Topics: Antitubercular Agents; Arrhythmias, Cardiac; Diarylquinolines; Drug Therapy, Combination; Humans; Tr | 2015 |
In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
Topics: Adenocarcinoma; Administration, Inhalation; Aerosols; Anti-Arrhythmia Agents; Antibiotics, Antituber | 2016 |
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Tolerance; Granulom | 2011 |